• Something wrong with this record ?

Alterations in DNA Damage Repair Genes Before and After Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer

U. Lemberger, B. Ernhofer, S. Krieger, A. Bruchbacher, A. Oszwald, E. Laukhtina, A. Haitl, MR. Hassler, B. Englinger, E. Compérat, SF. Shariat

. 2025 ; 71 (-) : 38-48. [pub] 20241205

Status not-indexed Language English Country Netherlands

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc25001879

BACKGROUND AND OBJECTIVE: The role of genetic variants in response to systemic therapy in muscle-invasive bladder cancer (MIBC) is still elusive. We assessed variations in genes involved in DNA damage repair (DDR) before and after cisplatin-based neoadjuvant chemotherapy (NAC) and correlation of alteration patterns with DNA damage and response to therapy. METHODS: Matched tissue from 46 patients with MIBC was investigated via Ion Torrent-based next-generation sequencing using a self-designed panel of 30 DDR genes. Phosphorylation of γ-histone 2A.X (H2AX) was analyzed via immunohistochemistry to evaluate DNA damage. Genetic variants were analyzed along with clinical data and quantitative phospho-H2AX data using the Kaplan-Meier method, Cox regression analysis, and factor analysis of mixed data. KEY FINDINGS AND LIMITATIONS: Twenty-five patients (54%) had a response (

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25001879
003      
CZ-PrNML
005      
20250123101956.0
007      
ta
008      
250117e20241205ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.euros.2024.10.022 $2 doi
035    __
$a (PubMed)39717660
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Lemberger, Ursula $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
245    10
$a Alterations in DNA Damage Repair Genes Before and After Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer / $c U. Lemberger, B. Ernhofer, S. Krieger, A. Bruchbacher, A. Oszwald, E. Laukhtina, A. Haitl, MR. Hassler, B. Englinger, E. Compérat, SF. Shariat
520    9_
$a BACKGROUND AND OBJECTIVE: The role of genetic variants in response to systemic therapy in muscle-invasive bladder cancer (MIBC) is still elusive. We assessed variations in genes involved in DNA damage repair (DDR) before and after cisplatin-based neoadjuvant chemotherapy (NAC) and correlation of alteration patterns with DNA damage and response to therapy. METHODS: Matched tissue from 46 patients with MIBC was investigated via Ion Torrent-based next-generation sequencing using a self-designed panel of 30 DDR genes. Phosphorylation of γ-histone 2A.X (H2AX) was analyzed via immunohistochemistry to evaluate DNA damage. Genetic variants were analyzed along with clinical data and quantitative phospho-H2AX data using the Kaplan-Meier method, Cox regression analysis, and factor analysis of mixed data. KEY FINDINGS AND LIMITATIONS: Twenty-five patients (54%) had a response (<pT2 pN0 cM0) to NAC. Responders had more somatic DDR gene variants in preNAC (53 vs 11; p < 0.001) and postNAC (51 vs 9; p = 0.038) tumor tissue in comparison to nonresponders, as well as significantly greater phosphorylation of H2AX after NAC. ERCC2 was significantly co-mutated with REV3L among responders. Owing to the small cohort, no specific mutation was significantly positively associated with therapy response. However, accumulation of CDK12, NBN, MSH3, MLH1, ATR, BRCA1, BRCA2, REVL3L, and SLX4 variants was observed for responders. CONCLUSIONS AND CLINICAL IMPLICATIONS: Patients with MIBC who responded to cisplatin-based NAC had more somatic DDR gene variants than nonresponders. Moreover, responders exhibited significantly greater DNA damage after NAC. PATIENT SUMMARY: Patients with muscle-invasive bladder cancer who have mutations in genes that are involved in repair of DNA damage are more likely to respond to cisplatin-based chemotherapy. Testing to identify these gene mutations could help in selecting the patients who are most likely to benefit from this treatment.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Ernhofer, Büsra $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
700    1_
$a Krieger, Sigurd $u Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria
700    1_
$a Bruchbacher, Andreas $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
700    1_
$a Oszwald, André $u Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria
700    1_
$a Laukhtina, Ekaterina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
700    1_
$a Haitl, Andrea $u Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria
700    1_
$a Hassler, Melanie R $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
700    1_
$a Englinger, Bernhard $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Center for Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
700    1_
$a Compérat, Eva $u Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Weill Cornell Medical College, New York, NY, USA $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czechia $u Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan
773    0_
$w MED00207999 $t European urology open science $x 2666-1683 $g Roč. 71 (20241205), s. 38-48
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39717660 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250117 $b ABA008
991    __
$a 20250123101950 $b ABA008
999    __
$a ok $b bmc $g 2254413 $s 1237882
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2025 $b 71 $c - $d 38-48 $e 20241205 $i 2666-1683 $m European urology open science $n Eur Urol Open Sci $x MED00207999
LZP    __
$a Pubmed-20250117

Find record

Citation metrics

Archiving options